Consolidated Statements of Equity - USD ($)	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	$ 4,066,480	$ 4,883,909	$ 100	$ 8,206	$ 410,372,049	$ 0	$ (404,788,809)	$ (707,637)	$ (817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	25,123,901	25,841,566					25,841,566		(717,665)
Unrealized loss on marketable securities	(28,717)	(28,717)				(28,717)
Share-based compensation (in shares)				54,545
Share-based compensation	2,412,981	2,412,981		$ 55	2,412,926
Net proceeds from issuance of common stock (in shares)				1,162,831
Net proceeds from issuance of common stock	5,678,632	5,678,632		$ 1,162	5,677,470
Proceeds from option exercises (in shares)				3,835
Proceeds from option exercises	13,576	13,576		$ 4	13,572
Elimination of equity associated with PCT sale	(3,686,526)	0							(3,686,526)
Conversion of redeemable securities	19,400,000	14,733,908			14,733,908				4,666,092
Change in ownership in subsidiary	0	(203,145)			(203,145)				203,145
Ending Balance (shares) at Sep. 30, 2017			10,000	9,427,001
Ending Balance at Sep. 30, 2017	52,980,327	53,332,710	$ 100	$ 9,427	433,006,780	(28,717)	(378,947,243)	(707,637)	(352,383)
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Ending Balance (shares) at Dec. 31, 2017			10,000	9,483,911
Ending Balance at Dec. 31, 2017	50,189,786	50,508,069	$ 100	$ 9,484	433,044,209	(27,978)	(381,810,109)	(707,637)	(318,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(12,610,857)	(12,609,146)					(12,609,146)		(1,711)
Unrealized loss on marketable securities	(643)	(643)				(643)
Share-based compensation (in shares)				126,759
Share-based compensation	1,878,545	1,878,545		$ 127	1,878,418
Net proceeds from issuance of common stock (in shares)				164,896
Net proceeds from issuance of common stock	997,709	997,709		$ 165	997,544
Proceeds from option exercises (in shares)				77,497
Proceeds from option exercises	354,740	354,740		$ 77	354,663
Change in ownership in subsidiary	0	(47,547)			(47,547)				47,547
Ending Balance (shares) at Sep. 30, 2018			10,000	9,853,063
Ending Balance at Sep. 30, 2018	$ 40,809,280	$ 41,081,727	$ 100	$ 9,853	$ 436,227,287	$ (28,621)	$ (394,419,255)	$ (707,637)	$ (272,447)